Market Cap 92.78M
Revenue (ttm) 0.00
Net Income (ttm) -21.68M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 85,651
Avg Vol 181,504
Day's Range N/A - N/A
Shares Out 51.26M
Stochastic %K 59%
Beta -0.03
Analysts Strong Sell
Price Target $9.56

Company Profile

TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to dev...

Industry: Biotechnology
Sector: Healthcare
Phone: 813 875 6600
Address:
10500 University Center Drive, Suite 110, Tampa, United States
justiceforb_85
justiceforb_85 Dec. 4 at 9:06 PM
$HURA finally some positive movement!
0 · Reply
Gamecock1
Gamecock1 Dec. 4 at 6:37 PM
$HURA where’s them CVRs at?
0 · Reply
sunsinga
sunsinga Dec. 3 at 4:10 AM
$HURA Is this worth watching this one ?Anything in pipeline ?
1 · Reply
Trapped
Trapped Nov. 27 at 12:23 AM
$HURA on watch…waiting for the hatch
0 · Reply
Gotsomescrewsmissing
Gotsomescrewsmissing Nov. 26 at 4:25 PM
$HURA my CVR'S got funded!!!! Just kidding
1 · Reply
Carico13
Carico13 Nov. 24 at 5:19 PM
$CHAI $CATX.X $HURA $URGN We are off to a great start folks 👀
1 · Reply
Carico13
Carico13 Nov. 23 at 1:21 AM
Monday Watchlist — Technical Setups Under $$3 $CHAI – Fresh 6-K confirms $91M FY24 and a $70M+ 2025 run-rate. Trading at a fraction of normal revenue multiples with a micro-float structure. Volatility has tightened and momentum is building above key demand zones. Any volume surge or PR could trigger a sharp re-rate move. $CATX – Biotech holding a strong base near major support. Accumulation is increasing, and December clinical data windows create asymmetric upside. Watching for a trend break with rising volume. $HURA – Low-float energy play that reacts aggressively to volume spikes. Sitting in a tightening wedge with room for a momentum breakout on any sector strength. $URGN – Urogen Pharma (bonus under $$3 when discounted in AH) Price Range: Recently dipped below $$3 Setup: Heavily oversold biotech with strong cash runway Catalyst: Early-2026 pipeline news seeded with Q4 commentary Why It's On Watch: One PR can trigger significant corrective move.
2 · Reply
Love_To_Learn
Love_To_Learn Nov. 19 at 8:32 PM
0 · Reply
bulllzguy
bulllzguy Nov. 19 at 5:58 PM
$HURA i told you to sell everything
0 · Reply
jayyflash
jayyflash Nov. 19 at 5:20 PM
$HURA This was yesterday’s good news of finished acquisition and yet some market manipulator/ HF/ short brought it down to $1.81. ´This strategic move is expected to enhance TuHURA’s market position and operational capabilities.’. Whenever they decide to stop manipulating it , this should be closer to $7 and above.
0 · Reply
Latest News on HURA
TuHURA Biosciences Completes Acquisition of Kineta

Jun 30, 2025, 8:50 AM EDT - 5 months ago

TuHURA Biosciences Completes Acquisition of Kineta


TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D.

Mar 11, 2025, 8:05 AM EDT - 9 months ago

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D.


justiceforb_85
justiceforb_85 Dec. 4 at 9:06 PM
$HURA finally some positive movement!
0 · Reply
Gamecock1
Gamecock1 Dec. 4 at 6:37 PM
$HURA where’s them CVRs at?
0 · Reply
sunsinga
sunsinga Dec. 3 at 4:10 AM
$HURA Is this worth watching this one ?Anything in pipeline ?
1 · Reply
Trapped
Trapped Nov. 27 at 12:23 AM
$HURA on watch…waiting for the hatch
0 · Reply
Gotsomescrewsmissing
Gotsomescrewsmissing Nov. 26 at 4:25 PM
$HURA my CVR'S got funded!!!! Just kidding
1 · Reply
Carico13
Carico13 Nov. 24 at 5:19 PM
$CHAI $CATX.X $HURA $URGN We are off to a great start folks 👀
1 · Reply
Carico13
Carico13 Nov. 23 at 1:21 AM
Monday Watchlist — Technical Setups Under $$3 $CHAI – Fresh 6-K confirms $91M FY24 and a $70M+ 2025 run-rate. Trading at a fraction of normal revenue multiples with a micro-float structure. Volatility has tightened and momentum is building above key demand zones. Any volume surge or PR could trigger a sharp re-rate move. $CATX – Biotech holding a strong base near major support. Accumulation is increasing, and December clinical data windows create asymmetric upside. Watching for a trend break with rising volume. $HURA – Low-float energy play that reacts aggressively to volume spikes. Sitting in a tightening wedge with room for a momentum breakout on any sector strength. $URGN – Urogen Pharma (bonus under $$3 when discounted in AH) Price Range: Recently dipped below $$3 Setup: Heavily oversold biotech with strong cash runway Catalyst: Early-2026 pipeline news seeded with Q4 commentary Why It's On Watch: One PR can trigger significant corrective move.
2 · Reply
Love_To_Learn
Love_To_Learn Nov. 19 at 8:32 PM
0 · Reply
bulllzguy
bulllzguy Nov. 19 at 5:58 PM
$HURA i told you to sell everything
0 · Reply
jayyflash
jayyflash Nov. 19 at 5:20 PM
$HURA This was yesterday’s good news of finished acquisition and yet some market manipulator/ HF/ short brought it down to $1.81. ´This strategic move is expected to enhance TuHURA’s market position and operational capabilities.’. Whenever they decide to stop manipulating it , this should be closer to $7 and above.
0 · Reply
WRX_FUN
WRX_FUN Nov. 19 at 5:04 PM
$CHAI $CATX $CLYM $HURA $URG OMG LMAO Now he has watch lists and a new avatar. 🤣
1 · Reply
Carico13
Carico13 Nov. 19 at 2:29 AM
$HURA Most traders overlook it, but $HURA is sitting at a price you normally never see for a company this deep into clinical development. Phase-3 is the stage where the real value gets created; it’s the closest step before commercialization or partnership interest. And right now? It’s trading like nobody expects anything. Oversold, low sentiment, low expectations. But Phase-3 catalysts don’t care about sentiment, when data drops, the entire valuation can re-rate instantly. Biotech history shows these sub-$$2 Phase-3 names can move violently on any positive update. Not a guaranteed run… but definitely one of the most asymmetric setups under $3.
1 · Reply
Carico13
Carico13 Nov. 19 at 2:05 AM
Wednesday watchlist $CHAI Oversold and trading way below its $91M pro forma valuation. Ultra-tight float + overdue PR window makes it a high-reward reversal setup. $CATX Biotech with analyst price targets massively above current levels. Clinical-stage oncology play with potential major trial catalysts. $CLYM Early-stage biotech sitting in an oversold range. Known for sharp moves when PR drops; solid low-priced setup. $HURA Phase-3 oncology company — the most meaningful catalyst stage. Under $2.X with high-impact clinical milestones ahead. $URG Low-priced uranium name tied to sector momentum. Often spikes on commodity or policy news; forming a bullish recovery base.
1 · Reply
ZacksSCR
ZacksSCR Nov. 17 at 9:07 PM
$HURA: Third Quarter Results https://buff.ly/cyZK53w
0 · Reply
bulllzguy
bulllzguy Nov. 17 at 7:47 PM
$HURA scam, sell everything
0 · Reply
letsgoobulls
letsgoobulls Nov. 17 at 5:55 PM
$HURA Am I going to lose my entire investment?
1 · Reply
NiX2000
NiX2000 Nov. 17 at 5:36 PM
$HURA scamco
0 · Reply
joe77w
joe77w Nov. 16 at 7:15 AM
$HURA ACTIVE NOT RECRUITING
1 · Reply
joe77w
joe77w Nov. 15 at 4:08 PM
$HURA https://clinicaltrials.gov/study/NCT05374915?term=Kintara&rank=1
1 · Reply
joe77w
joe77w Nov. 15 at 4:01 PM
$HURA update expected in december imo
0 · Reply
JarvisFlow
JarvisFlow Nov. 14 at 7:26 PM
Maxim Group updates rating for TuHURA Biosciences ( $HURA ) to Buy, target set at 15 → 8.
0 · Reply
cranio_verde
cranio_verde Nov. 14 at 12:28 PM
$HURA https://finance.yahoo.com/news/tuhura-biosciences-inc-reports-third-120000472.html?guccounter=1
0 · Reply